VRK1 and central nervous system cancer: Immunohistochemistry showed that the expression levels of VRK1, YBX1, and SOX2 were significantly reduced in the A/TMZ‐siVRK1 group compared to those in the PBS, TMZ‐siVRK1, A/TMZ‐siNC, and A/PLGA‐siVRK1 groups, indicating that A/TMZ‐siVRK1 inhibited VRK1/YBX1/SOX2 signal activation in gliomas (Figure 10G).